OSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Immune Checkpoint CLEC-1in Journal of Immunology Nantes, France – April 2, 2024 – 7:30 am CET – OSE.
Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) today announced the publication of data in the peer-reviewed journal Science Advances on a first-in-classpreclinical